Ori Biotech’s Post

Read my White Paper on a Robust Chain of Custody in CGT ahead of #MeetingontheMesa. Learn more about CTI Clinical Trial and Consulting Services and how our expertise in #CGT can better support you!

Leaders from #AskBio and Shanghai-based Belief BioMed (BBM) earlier this week signed a collaboration agreement that will enable both companies to combine efforts and experience in #GeneTherapy technology to explore potential therapies for diseases that may be treatable using a liver-targeted approach. This strategic collaboration is an excellent example of how we work at AskBio. Collaborating with innovative, like-minded partners with complementary gene therapy expertise enables us to find the best way forward for our pipeline assets and bolster our efforts to advance new therapies for conditions with significant unmet need. #Leadership Jane Zheng, Philip Sin, Dr. Xiao Xiao, Tracy Dowling, Gustavo Pesquin

The advent of cell and gene therapies is a promising shift in the healthcare landscape, yet it isn't without its unique challenges. From intricate manufacturing phases to regulatory complexities, these obstacles must be navigated for its full potential to be realized. In a recent interview with Clinical Leader, Roger Palframan, Head of US Research UCB, explores these issues - offering insight into how we can overcome them. Read it now: https://lnkd.in/dVvGxRE7 #CellAndGeneTherapy #HealthcareInnovation

With 2023 officially in the books, we’re looking back at the top #pharmainsights published on our blog from throughout the year. These are the top-performing blogs that #pharmaprofessionals like you read the most in 2023: 1. CROs vs CMOs vs CDMOs: What’s the difference between the three? https://lnkd.in/eMBRN9BU 2. Technology transfer process for commercial viral vector manufacturing: https://lnkd.in/eMRSTyXU 3. Delivering on the promise of cell and gene therapies: A patient-centric approach: https://lnkd.in/eRPpE_su To read these insights and many others, visit our blog: https://lnkd.in/eqefh4fs

Join us October 3 to explore common challenges and considerations for seamless viral vector tech transfer: https://okt.to/GDyBow Freda Cuneo and Kevin Taylor, MSAT experts in upstream and downstream production with more than three decades of combined experience, join Dr. James Cody to share valuable insights and lessons learned: - Approaches to bolster your program - MSAT best practices to avoid roadblocks - Real-world case study examples Cell & Gene Therapy Insights BioInsights #viralvectortechtransfer #viralvectors #cellandgenetherapy #genetherapy #msat

The BioIndustry Association (BIA) has published its report on the UK's 2023 #cellandgenetherapy landscape! With 23 cell and gene therapies now approved for use in the UK, the rapidly growing sector is poised to play a key role in the future of healthcare. The BIA's in-depth report solidifies the UK's position at the forefront of research in this field. 🟡 47 advanced therapy developers are headquartered in the UK 🟡 Over 6,000 people working in the sector 🟡 Raised 55% of total European VC funding in 2023 🟡 84 advanced therapies are currently in development in the UK Read the full report here: https://bit.ly/3IlsEah

The “hf” in hfCas12Max stands for high-fidelity, and it’s not just a label—it's fact. hfCas12Max surpasses other common CRISPR nucleases by delivering high on-target editing with minimized off-target editing, which is critical for developing precise and effective #crispr -based cell and gene therapies. See for yourself how hfCas12Max is the right nuclease for you: https://lnkd.in/g7FjR7Gf

The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate. Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.

The rapid evolution of cell and gene therapies (CGTs) has been incredible, with the FDA approving seven new therapies in 2023 alone. This growth is encouraging, but we still have hurdles to overcome, from ensuring healthcare systems are prepared to handle these complex treatments to addressing high costs. One trend catching my attention, which I was happy to write about in-depth with Kyle Felmet, is the shift toward rare diseases and autoimmune conditions fuelled by advancements in gene-editing technologies. These innovations, combined with AI's potential to navigate complex processes, optimise manufacturing and enhance patient outcomes, offer new avenues for more effective treatments and value-based pricing models. Like any life science innovation, we must remain focused on driving patient access and affordability while equipping healthcare systems to deliver these groundbreaking CGTs.

Interesting speaker announcement!   Be part of the Data & Analytics Forum 2024   We are pleased to announce Akbar Mustafa from Roche as one of our speakers who will give insights into the topic "Cell and Gene Therapy - Data Management for Individualized Treatments ". 🚀   In a rapidly evolving field like cell and gene therapy, robust data management is key for personalized healthcare solutions.   Don't miss this opportunity! Save the date and register now for the Data & Analytics Forum 2024 in Frankfurt   #CAMELOTManagementForum #DataAnalytics #DataManagement